Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Health
Vandana Singh

Twist Bioscience Launches Synthetic RNA Positive Controls For SARS-CoV-2 Encapsulated Minicapsules

Twist Bioscience Corporation (NASDAQ:TWST) has launched specific synthetic RNA positive controls for SARS-CoV-2 encapsulated in stainless steel mini capsules that Imagene SA provided. 

  • The airtight mini capsules provide a stable environment for the RNA controls, allowing cost-effective shipping and storage at room temperature of fragile RNA for an extended period. 
  • In particular, the product enhancement will enable Twist to serve customers in regions that do not have an effective cold chain system or easy access to ultra-cold storage and also allow the use of the controls in point of care settings.
  • This is an expansion of Twist's first agreement with Imagene in July 2019 to use Imagene's DNAshell technology for long-term storage of digital data encoded in DNA. Using Imagene's encapsulation technology, Twist now can ship and store both DNA and RNA products for long periods. 
  • The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome, and are sequence-verified. 
  • Price Action: TWST shares are down 4.81% at $48.14 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.